Gene editing screens under immune pressure identify CHD1 and MAP3K7 as factors linked to cancer immunotherapy resistance

CHD1 and MAP3K7 loss may make cancer cells more vulnerable to anti-tumor T cells and immune checkpoint blockade.

This preclinical and translational study used whole-genome CRISPR-Cas9 screens in tumoroid-T cell co-cultures, cancer cell models, cytokine contexts, a syngeneic mouse melanoma model, and patient tumor-response correlations.

The therapeutic and biomarker claims rest mainly on model systems and correlative patient tumor data rather than prospective clinical testing.